<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26590" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Papanicolaou Smear</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kitchen </surname>
            <given-names>Felisha L.</given-names>
          </name>
          <aff>Coliseum Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cox</surname>
            <given-names>Christina M.</given-names>
          </name>
          <aff>Coliseum Health Systems</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Felisha Kitchen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christina Cox declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26590.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>In the 1940s, cervical cancer was a leading cause of death for women of childbearing age in the United States. Dr&#x000a0;George Papanicolaou, a Greek immigrant, initially began his academic career studying the reproductive cycles of guinea pigs. After moving to the United States, he held a position in the anatomy department at Cornell University. He changed his focus of study to human physiology and began collaborating with gynecological pathologist Dr Herbert Traut. While working together at Cornell University, they published <italic toggle="yes">Diagnosis of Uterine Cancer by the Vaginal Pap Smear</italic> in 1943. This significant work detailed how normal and abnormal vaginal and cervical cells could be observed under a microscope and how they should be classified. Shortly thereafter, the Pap smear became the gold standard in cervical cancer screening and remains the primary screening tool for cervical cancer today.<xref ref-type="bibr" rid="article-26590.r1">[1]</xref><xref ref-type="bibr" rid="article-26590.r2">[2]</xref><xref ref-type="bibr" rid="article-26590.r3">[3]</xref><xref ref-type="bibr" rid="article-26590.r4">[4]</xref></p>
      </sec>
      <sec id="article-26590.s2" sec-type="Etiology and Epidemiology">
        <title>Etiology and Epidemiology</title>
        <p>In the United States, the death rate due to cervical cancer has declined by more than 60%&#x000a0;since the 1950s.<bold>&#x000a0;</bold>In the past, cervical cancer was one of the most common cancers affecting&#x000a0;women of childbearing age, but over time, its occurrence has significantly decreased. Today, it ranks as the 14th most common&#x000a0;cancer among these women, indicating a marked reduction in both incidence and impact.</p>
        <p>In 2010, approximately 12,000 women were diagnosed with cervical cancer, resulting in approximately 4000 deaths. Between 2002 and 2012, the rate of cervical cancer decreased by 1.3%, and deaths from cervical cancer decreased by 0.9%. In 2014, Hispanic women were reported&#x000a0;to have the highest rate&#x000a0;of&#x000a0;cervical cancer diagnoses, whereas African-American women had the highest death rate from the disease.<xref ref-type="bibr" rid="article-26590.r5">[5]</xref><xref ref-type="bibr" rid="article-26590.r6">[6]</xref><xref ref-type="bibr" rid="article-26590.r7">[7]</xref></p>
        <p>Cervical cancer is much more common in countries without widespread screening programs. More than 80% of cervical cancer cases are found in developing countries. Cervical cancer is still the third most common cause of cancer in women worldwide. Annually, there are approximately 528,000 new cases of cervical cancer, with 266,000 deaths. These statistics&#x000a0;make it the second most common cause of cancer-related death in women.</p>
      </sec>
      <sec id="article-26590.s3" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>In the 1980s, researchers discovered that nearly all cervical cancer cases were caused by human papillomavirus (HPV).&#x000a0;There are more than 100 types of HPV, and 40 can be&#x000a0;transmitted sexually, whereas 15 are considered high-risk HPV or cancer-causing. There are&#x000a0;2 subtypes of HPV&#x02014;HPV 16 and 18, which are responsible&#x000a0;for about 70% of cervical cancers worldwide.</p>
        <p>Cervical infection with high-risk HPV is typically required for the development of cervical cancer. However, HPV infection alone is not sufficient for progression to neoplasia. Most infections with high-risk HPV are transient and do not progress to cervical intraepithelial neoplasia (CIN). A small percentage of women infected with high-risk HPV develop cervical cancer. Cigarette smoking, a weakened immune system, and HIV infection are all factors contributing to the persistence of HPV.<xref ref-type="bibr" rid="article-26590.r8">[8]</xref><xref ref-type="bibr" rid="article-26590.r9">[9]</xref><xref ref-type="bibr" rid="article-26590.r10">[10]</xref><xref ref-type="bibr" rid="article-26590.r11">[11]</xref></p>
      </sec>
      <sec id="article-26590.s4" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>In 2009, the American College of Obstetricians and Gynecologists (ACOG) recommended that women begin Pap smear screenings at 21. The ACOG also advises that women aged 21 to 29 undergo Pap smear testing every&#x000a0;3 years. For women aged 30 to 65, the ACOG recommends Pap smears with HPV testing every 5 years. Screening can generally be discontinued after 65. However, certain groups of women should be screened more frequently for cervical cancer&#x000a0;compared to the general population, which include women infected with HIV; immunocompromised women, such as organ transplant patients; women exposed to diethylstilbestrol while in utero; and&#x000a0;those&#x000a0;previously treated for CIN 2, CIN 3, or cervical cancer.</p>
        <p>In 2018, the United States Preventive Services Task Force revised its guidelines as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade A recommendation: Screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Grade A recommendation:&#x000a0;Screening every 3 years with cervical cytology alone, every 5 years with hrHPV testing alone, or every 5 years with hrHPV testing combined with cytology (co-testing) in women aged 30 to 65.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Grade&#x000a0;D recommendation: No&#x000a0;screening for cervical cancer in women younger than 21.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Grade&#x000a0;D recommendation:&#x000a0;No&#x000a0;screening for cervical cancer in women older than 65 who have had adequate prior screening and are not otherwise at high risk for the disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Grade&#x000a0;D recommendation:&#x000a0;Screening for cervical cancer in women who have had a hysterectomy with removal of the cervix and do not have a history of a high-grade precancerous lesion or cervical cancer.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26590.s5" sec-type="Diagnostic Tests">
        <title>Diagnostic Tests</title>
        <p>Women with epithelial cell abnormalities on Pap smear should be further tested with colposcopy and biopsy (see <bold>Image.</bold> Squamous Cells with Acute Inflammation). A colposcope is a binocular microscope that allows visual inspection of the cervix. Gross abnormalities visualized on colposcopy can then be biopsied for further classification.</p>
      </sec>
      <sec id="article-26590.s6" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>There are&#x000a0;2 acceptable techniques for collecting the Pap smear&#x02014;liquid-based and conventional. In both methods, a clinician inserts a speculum into the woman's vagina and identifies the cervix. The liquid-based method involves collecting cells from the transformation zone of the cervix using a brush and transferring the cells to a vial of liquid preservative. The conventional technique involves collecting cells from the transformation zone of the cervix using a brush and spatula, transferring the cells to a slide, and fixing the slide with a preservative. The liquid-based technique allows testing for HPV, gonorrhea, and chlamydia from a single collection. Theoretically, the liquid-based technique has the advantages of more straightforward interpretation, fewer unsatisfactory results, and the filtration of blood and debris.</p>
      </sec>
      <sec id="article-26590.s7" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>Vaginal discharge, blood, and lubricants can interfere with the interpretation of Pap smears. When performing Pap smears, many healthcare professionals&#x000a0;use water or a small amount of water-based lubricant to minimize patient discomfort.</p>
      </sec>
      <sec id="article-26590.s8" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>
<bold>Bethesda System for Reporting Cervical Cytology</bold>
</p>
        <p>The Bethesda System for Reporting Cervical Cytology is a standardized classification system used in the United States for interpreting Pap smear results and has been in place since 1988. The most recent update was made in 2014. This system provides clear guidelines for reporting and interpreting cervical cytology findings, which aids in the management and diagnosis of cervical abnormalities.</p>
        <p>
<bold>Components of the Bethesda system:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Specimen type:&#x000a0;Indicates whether the sample is conventional or liquid-based</p>
          </list-item>
          <list-item>
            <p>Specimen adequacy:&#x000a0;Indicates whether the specimen&#x000a0;is satisfactory or unsatisfactory for evaluation</p>
          </list-item>
          <list-item>
            <p>General categorization
<list list-type="bullet"><list-item><p>Negative for intraepithelial lesion or malignancy</p></list-item><list-item><p>Other</p></list-item><list-item><p>Epithelial cell abnormality</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;Interpretation/results:
<list list-type="bullet"><list-item><p>Negative intraepithelial lesion: No cellular evidence of neoplasia)</p></list-item><list-item><p>Nonneoplastic findings: Includes non-neoplastic cellular variations, reactive cellular changes, and glandular cells in post-hysterectomy</p></list-item><list-item><p>Organisms: Detection of <italic toggle="yes">Trichomonas vaginalis</italic>, bacterial vaginosis,&#x000a0;<italic toggle="yes">Candida</italic> species,&#x000a0;<italic toggle="yes">Actinomyces</italic> species, and cellular changes consistent with herpes virus&#x000a0;and cytomegalovirus</p></list-item><list-item><p>Other</p></list-item><list-item><p>Endometrial cells in a woman older than 45</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold> Epithelial cell abnormalities:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Squamous cell:
<list list-type="bullet"><list-item><p>Atypical squamous cells (ASCs)
<list list-type="bullet"><list-item><p>ASCs of undetermined significance (ASC-US) &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p></list-item><list-item><p>Cannot exclude high-grade squamous intraepithelial lesion (ASC-H)</p></list-item></list>
</p></list-item><list-item><p>Low-grade squamous intraepithelial lesion: Mild dysplasia or CIN 1</p></list-item><list-item><p>High-grade squamous intraepithelial lesion: Moderate and severe dysplasia, corresponding to CIN 2 and CIN 3</p></list-item><list-item><p>With features suspicious for invasion&#x000a0;if invasion is suspected</p></list-item><list-item><p>Squamous cell carcinoma</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Glandular cell:
<list list-type="bullet"><list-item><p>Endocervical cells (not otherwise specified)</p></list-item><list-item><p>Endometrial cells (not otherwise specified)</p></list-item><list-item><p>Glandular cells (not otherwise specified)</p></list-item><list-item><p>Endocervical cells favor neoplastic</p></list-item><list-item><p>Glandular cells favor neoplastic</p></list-item><list-item><p>Endocervical adenocarcinoma in situ</p></list-item><list-item><p>Adenocarcinoma endocervical
<list list-type="bullet"><list-item><p>Endometrial</p></list-item><list-item><p>Extrauterine</p></list-item><list-item><p>Not otherwise specified</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Other malignant neoplasms</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26590.s9" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Since the discovery of HPV subtypes causing most cervical cancer cases,&#x000a0;2 vaccines have been developed to reduce the incidence of new cervical cancer cases. The bivalent vaccine offers protection against HPV subtypes 16 and 18, whereas the quadrivalent vaccine provides protection not only against HPV 16 and 18 but also for subtypes 6 and 11, which cause 90% of genital warts.&#x000a0;Ongoing research continues to focus on developing vaccines for the prevention of cervical cancer.</p>
      </sec>
      <sec id="article-26590.s10" sec-type="Quality Control and Lab Safety&#x0000d;&#x0000a;">
        <title>Quality Control and Lab Safety
</title>
        <p>A computer-aided automated device can interpret Pap smear specimens. When using a computer-aided system, the Bethesda System for Reporting Cervical Cytology requires documentation of the device and its results.</p>
      </sec>
      <sec id="article-26590.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The interprofessional team plays a vital role in improving patient care and outcomes related to Pap smears. This collaborative approach involves various healthcare professionals, including gynecologists, primary care physicians, nurses, pathologists, and laboratory technicians. Each member contributes unique expertise, enhancing the quality of care provided to patients.</p>
        <p>Collaboration begins with clear communication among team members regarding screening guidelines, patient history, and individual risk factors for cervical cancer. Regular interdisciplinary meetings allow the team to review and discuss cases, share insights on interpreting Pap smear results, and develop shared protocols for follow-up care based on findings.</p>
        <p>In addition, ongoing interprofessional continuing education initiatives allow healthcare professionals to stay updated on best practices and emerging evidence. This shared learning experience fosters an environment where each team member understands their role in the care continuum and the importance of their contributions. By recognizing and valuing each team member's contributions, the interprofessional team can effectively flatten the hierarchy in healthcare, leading to improved patient outcomes and a more integrated approach to cervical cancer prevention and care.</p>
      </sec>
      <sec id="article-26590.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26590&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26590">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26590/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26590">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-26590.s13">
        <fig id="article-26590.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Squamous Cells with Acute Inflammation. The image shows a microscopic examination of squamous cells with acute inflammation, captured at &#x000d7;40 magnification and stained using the Papanicolaou stain. Contributed by F Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pmn__squamo02" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-26590.s14">
        <title>References</title>
        <ref id="article-26590.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanford</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Sher</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Rebbeck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aizer</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Mahal</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Cancer Screening Patterns Among Current, Former, and Never Smokers in the United States, 2010-2015.</article-title>
            <source>JAMA Netw Open</source>
            <year>2019</year>
            <month>May</month>
            <day>03</day>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>e193759</fpage>
            <pub-id pub-id-type="pmid">31099863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26590.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nogueira-Rodrigues</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>HPV Vaccination in Latin America: Global Challenges and Feasible Solutions.</article-title>
            <source>Am Soc Clin Oncol Educ Book</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>39</volume>
            <fpage>e45</fpage>
            <page-range>e45-e52</page-range>
            <pub-id pub-id-type="pmid">31099692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26590.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ge</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mody</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Luna</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Armylagos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Puntachart</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hendrickson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Mody</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>HPV status in women with high-grade dysplasia on cervical biopsy and preceding negative HPV tests.</article-title>
            <source>J Am Soc Cytopathol</source>
            <year>2019</year>
            <season>May-Jun</season>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>149</fpage>
            <page-range>149-156</page-range>
            <pub-id pub-id-type="pmid">31097291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26590.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Molberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thibodeaux</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rivera-Colon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lucas</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Challenges in the Pap diagnosis of endocervical adenocarcinoma in situ.</article-title>
            <source>J Am Soc Cytopathol</source>
            <year>2019</year>
            <season>May-Jun</season>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>141</fpage>
            <page-range>141-148</page-range>
            <pub-id pub-id-type="pmid">31097290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26590.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rukhadze</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lunet</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Peleteiro</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Cervical cytology use in Portugal: Results from the National Health Survey 2014.</article-title>
            <source>J Obstet Gynaecol Res</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>45</volume>
            <issue>7</issue>
            <fpage>1286</fpage>
            <page-range>1286-1295</page-range>
            <pub-id pub-id-type="pmid">31034140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26590.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swailes</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Hossler</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Kesterson</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Pathway to the Papanicolaou smear: The development of cervical cytology in twentieth-century America and implications in the present day.</article-title>
            <source>Gynecol Oncol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>154</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-7</page-range>
            <pub-id pub-id-type="pmid">30995961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26590.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corkum</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Shaddick</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jewlal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sugimoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Prefontaine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Souza</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>When Pap Testing Fails to Prevent Cervix Cancer: A Qualitative Study of the Experience of Screened Women Under 50 with Advanced Cervix Cancer in Canada.</article-title>
            <source>Cureus</source>
            <year>2019</year>
            <month>Jan</month>
            <day>24</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>e3950</fpage>
            <pub-id pub-id-type="pmid">30937248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26590.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stumbar</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feld</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Cervical Cancer and Its Precursors: A Preventative Approach to Screening, Diagnosis, and Management.</article-title>
            <source>Prim Care</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-134</page-range>
            <pub-id pub-id-type="pmid">30704652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26590.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santamar&#x000ed;a-Ulloa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valverde-Manzanares</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Inequality in the Incidence of Cervical Cancer: Costa Rica 1980-2010.</article-title>
            <source>Front Oncol</source>
            <year>2018</year>
            <volume>8</volume>
            <fpage>664</fpage>
            <pub-id pub-id-type="pmid">30687639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26590.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chrysostomou</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Stylianou</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Constantinidou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kostrikis</surname>
                <given-names>LG</given-names>
              </name>
            </person-group>
            <article-title>Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing.</article-title>
            <source>Viruses</source>
            <year>2018</year>
            <month>Dec</month>
            <day>19</day>
            <volume>10</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">30572620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26590.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Screening for Cervical Cancer.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Aug</month>
            <day>21</day>
            <volume>320</volume>
            <issue>7</issue>
            <fpage>732</fpage>
            <pub-id pub-id-type="pmid">30140878</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
